摘要
卵巢癌的早期诊断除了经典的肿瘤标记物癌抗原125(cancer antigen 125,CA_125)及经阴道超声(transvaginal ultrasonography,TVS)以外,新型标志物人附睾蛋白4(human epididymis protein4,HE_4)及蛋白质组学对监测卵巢癌的发病、治疗效果、临床转归及复发等几个方面都有很好的临床意义。卵巢癌的初始治疗手术的规范性和彻底性,以及手术与化疗的合理配合至关重要。早期卵巢癌要进行全面的分期手术,必要时应该在化疗开始前进行再分期手术。晚期卵巢癌要尽量做到满意的肿瘤细胞减灭术,并要适时合理配合新辅助化疗。经过早期诊断和规范治疗,卵巢癌的生存率得到了明显上升,但较高的复发率及死亡率仍是妇科肿瘤医师不容忽视的问题。
The early diagnosis of ovarian cancer has been relied on the classical tumor marker cancer antigen 125 （CA125 ） ,as well as transvaginal uhrasonography （TVS）. Recently ,the new markers of human epididymis protein 4 （HE4 ） and proteomics become very important for monitoring ovarian cancer pathogenesis, treatment, clinical outcome and recurrence. The normative and thoroughness of the initial surgery for ovarian cancer are critical to the proper surgery and chemotherapy. Early ovarian cancer should conduct a comprehensive staging operation. When necessary, the re - staging should be done before chemotherapy. In advanced stage of ovarian cancer, it had better to do cytoreductive surgery, in combination with neoadjuvant chemotherapy. After early diagnosis and standard treatment, the survival rate of ovarian cancer has been increased significantly, however, gynecological oneologist can not ignore the high relapse rate and mortality.
出处
《中国计划生育和妇产科》
2013年第1期5-8,共4页
Chinese Journal of Family Planning & Gynecotokology
关键词
卵巢癌
诊断
手术治疗
化学治疗
ovarian cancer
diagnosis
surgery
chemotherapy
